NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN)
announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview
at two upcoming investor conferences:
- Baird 2016 Healthcare Conference on Wednesday, September 7, 2016 at 2:00 p.m. ET at the New York Palace in New York City, NY;
and
- The LEERINK Partners Rare Disease & Immuno-Oncology Roundtable on Wednesday, September 28, 2016 at 4:10 p.m. ET at the New
York Palace in New York City, NY.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the
Company's investor relations website, http://ir.achillion.com. The audio recording will be
archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of
the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage
its strengths across the continuum from discovery to commercialization in its goal of providing better treatments for people with
serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to pursue
best-in-class oral antiviral therapy for chronic hepatitis C (HCV) and build a platform of potent and specific complement
inhibitors. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing
life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors: Glenn Schulman Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 gschulman@achillion.com Media: Liz Power Achillion Pharmaceuticals, Inc. Tel: (203) 752-5509 lpower@achillion.com
